Top Markets
#1 Status Status +19.98%
#2 Civic Civic +4.94%
#3 Hex Trust USD Hex Trust USD +4.50%
#4 City Boy City Boy +3.81%
#5 MANTRA MANTRA +3.65%
#6 Bitway Bitway +3.41%
#7 Infinity Ground Infinity Ground +3.25%
#8 龙虾 (Lobster) 龙虾 (Lobster) +3.15%
#9 Memetern Memetern +2.79%
#10 Raydium Raydium +2.78%
Coin of the day
Status Status
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Classifica tra le azioni #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Prezzo delle azioni
$451.59
Capitalizzazione di mercato
$114.70B
Variazione (1 giorno)
-2.36%
Variazione (1 anno)
-11.89%
Paese
US
Scambia Vertex Pharmaceuticals Incorporated (VRTX)

Categoria

Healthcare
Rapporto P/S per Vertex Pharmaceuticals Incorporated (VRTX)
Rapporto P/S al March 2026 TTM: 9.90
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Vertex Pharmaceuticals Incorporated, il rapporto P/S attuale (TTM) è 9.90. Alla fine del 2023, era pari a 10.62.
Storico del rapporto P/S per Vertex Pharmaceuticals Incorporated da 2000 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
2026 (TTM) 9.90 5.24%
2024 9.41 -11.43%
2023 10.62 28.30%
2022 8.28 10.84%
2021 7.47 -24.50%
2020 9.90 -26.71%
2019 13.50 -2.34%
2018 13.83 -7.73%
2017 14.99 42.14%
2016 10.54 -64.09%
2015 29.36 -38.95%
2014 48.08 248.85%
2013 13.78 137.01%
2012 5.82 20.56%
2011 4.82 -90.15%
2010 48.96 -32.70%
2009 72.75 199.01%
2008 24.33 61.60%
2007 15.06 -23.11%
2006 19.58 27.59%
2005 15.35 89.82%
2004 8.09 -29.86%
2003 11.53 54.66%
2002 7.45 -31.82%
2001 10.93 -82.35%
2000 61.94 0.00%
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.55 -64.14%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.40 -45.44%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.14 -38.02%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.04 -69.26%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.90 30.24%
NL